# SAD Study of APR002 Investigating the Safety/Tolerability, Pharmacokinetics/Pharmacodynamics in Healthy Subjects

> **NCT05268198** · EARLY_PHASE1 · COMPLETED · sponsor: **Global Health Drug Discovery Institute** · enrollment: 42 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** APR002
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05268198
- **Lead sponsor:** Global Health Drug Discovery Institute
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-20
- **Primary completion:** 2023-06-29
- **Final completion:** 2023-07-27
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2023-08-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05268198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05268198, "SAD Study of APR002 Investigating the Safety/Tolerability, Pharmacokinetics/Pharmacodynamics in Healthy Subjects". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05268198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*